Research programme: monoclonal antibody biosimilars - TOT Biopharm

Drug Profile

Research programme: monoclonal antibody biosimilars - TOT Biopharm

Alternative Names: BCIA07; TAA013; TAB 014; TAD 011; TAT014; TOT104

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TOT Biopharm
  • Developer Lees Pharmaceutical Holdings; TOT Biopharm
  • Class Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Mantle-cell lymphoma; Solid tumours; Wet age-related macular degeneration

Most Recent Events

  • 09 Jan 2017 TOT Biopharm files an IND application with the CFDA in China
  • 05 Jan 2017 TAB 014 licensed to Lees Pharmaceutical Holdings in China, Hong Kong and Macau
  • 05 Jan 2017 Early research in Wet age-related macular degeneration in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top